



Isodiol International Inc. Announces Appointment of New Chief Financial Officer

August 29, 2018 - Vancouver, BC – [Isodiol International Inc.](#) (CSE: [ISOL](#)) (OTC:[ISOLF](#)) (FSE: [LB6A.F](#)) (the “Company”), a global CBD innovator and leader specializing in hemp-based health and wellness products, announces that Mr. Eli Dusenbury, CPA, CA, has been appointed as the Company’s new Chief Financial Officer. Mr. Dusenbury has over 8 years of public accounting experience providing financial reporting, operational and assurance engagement services to a variety of both public and private sector entities reporting in Canada and the US.

With working experiences in both Canada and the US over a wide range of public and private companies, Mr. Dusenbury has gained in-depth understanding of business operations, control environments and strategic business decision-making, which provide a unique balance between both operational and accounting perspectives to resolve complex technical accounting, reporting and auditing issues.

Mr. Dusenbury is working closely with the Company’s management, legal counsel, and auditors to complete the Restated Financial Statements.

The Company wishes to thank outgoing Chief Financial Officer Bryan Loree for his service over the preceding 2 years through a period of extensive transition and acquisitions.

The Company will be restating its most recent annual audited financial statements with updated disclosures related to its business acquisitions and as a result, the Company expects it’s shares on the Canadian Securities Exchange to be trading shortly thereafter. The Company is currently working with its auditors and the BCSC to resolve this matter.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

[Isodiol International Inc.](#) is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nano-technology for the highest quality consumable and topical skin care products. Most recently, the company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products as was announced [April 26, 2018](#).

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its consumer products portfolio and aggressively continue international expansion into Latin America, Asia, and Europe.



Join Us On Facebook: <https://www.facebook.com/IsodiolInternationalInc/>

Twitter: [@IsodiolIntInc](https://twitter.com/IsodiolIntInc)

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

lr@isodiol.com

www.isodiol.com

Forward-Looking Information: *This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.*

The CSE has not reviewed, approved or disapproved the content of this press release.